Results 281 to 290 of about 311,875 (316)
Some of the next articles are maybe not open access.
Journal of the American Medical Association (JAMA), 2001
CONTEXT Atrial fibrillation is the most common arrhythmia in elderly persons and a potent risk factor for stroke. However, recent prevalence and projected future numbers of persons with atrial fibrillation are not well described.
A. Go +6 more
semanticscholar +1 more source
CONTEXT Atrial fibrillation is the most common arrhythmia in elderly persons and a potent risk factor for stroke. However, recent prevalence and projected future numbers of persons with atrial fibrillation are not well described.
A. Go +6 more
semanticscholar +1 more source
Current Opinion in Hematology, 2006
Abstract Traditional anticoagulant drugs, including unfractionated heparin and warfarin, have several limitations. New anticoagulants have been developed that target a single coagulation factor and have predictable dose-response relationships. These include direct thrombin inhibitors and factor Xa inhibitors.
AGNELLI, Giancarlo, BECATTINI, Cecilia
openaire +6 more sources
Abstract Traditional anticoagulant drugs, including unfractionated heparin and warfarin, have several limitations. New anticoagulants have been developed that target a single coagulation factor and have predictable dose-response relationships. These include direct thrombin inhibitors and factor Xa inhibitors.
AGNELLI, Giancarlo, BECATTINI, Cecilia
openaire +6 more sources
Clinical Obstetrics and Gynecology, 1998
Outpatient management of women requiring treatment and prophylaxis against thromboembolic conditions during pregnancy and the postpartum period requires a coordinated effort between the patient, her obstetrician and, in certain cases, a hematologic consultant.
H L, Brown, R A, Bobrowski
openaire +2 more sources
Outpatient management of women requiring treatment and prophylaxis against thromboembolic conditions during pregnancy and the postpartum period requires a coordinated effort between the patient, her obstetrician and, in certain cases, a hematologic consultant.
H L, Brown, R A, Bobrowski
openaire +2 more sources
Critical Care Medicine, 2021
Supplemental Digital Content is available in the text. OBJECTIVES: Extracorporeal membrane oxygenation is a life-sustaining therapy for severe respiratory failure. Extracorporeal membrane oxygenation circuits require systemic anticoagulation that creates
R. Rivosecchi +11 more
semanticscholar +1 more source
Supplemental Digital Content is available in the text. OBJECTIVES: Extracorporeal membrane oxygenation is a life-sustaining therapy for severe respiratory failure. Extracorporeal membrane oxygenation circuits require systemic anticoagulation that creates
R. Rivosecchi +11 more
semanticscholar +1 more source
Pharmacology of Anticoagulants
Disease-a-Month, 2012Antithrombotic drugs are used for the prevention and treatment of thrombosis. Targeting the various components of thrombosis, these agents include (1) antiplatelet agents; (2) anticoagulants; and (3) fibrinolytic agents. This review focuses on anticoagulants.
Loke, Chandravathi, MD +2 more
openaire +3 more sources
COVID-19 and Its Implications for Thrombosis and Anticoagulation
Seminars in Respiratory and Critical Care Medicine, 2021Venous thromboembolism, occlusion of dialysis catheters, circuit thrombosis in extracorporeal membrane oxygenation (ECMO) devices, acute limb ischemia, and isolated strokes, all in the face of prophylactic and even therapeutic anticoagulation, are ...
S. Berkman, V. Tapson
semanticscholar +1 more source
American Journal of Gastroenterology, 2021
INTRODUCTION: Current guidelines recommend anticoagulation as the mainstay of portal vein thrombosis (PVT) treatment in cirrhosis. However, because of the heterogeneity of PVT, anticoagulation alone does not always achieve satisfactory results.
Yong Lv +16 more
semanticscholar +1 more source
INTRODUCTION: Current guidelines recommend anticoagulation as the mainstay of portal vein thrombosis (PVT) treatment in cirrhosis. However, because of the heterogeneity of PVT, anticoagulation alone does not always achieve satisfactory results.
Yong Lv +16 more
semanticscholar +1 more source
Novel anticoagulants and the future of anticoagulation
Thrombosis Research, 2009Since its discovery during the first half of the 20th century by biochemists at the University of Wisconsin, warfarin (along with other vitamin K antagonists) has remained the only oral anticoagulant available to patients at risk for thromboembolism. After nearly 6 decades in clinical practice, we have learned much about warfarin. Although it is highly
openaire +3 more sources
2006
Because of the narrow therapeutic index of warfarin and unfractionated heparin (UFH), monitoring their anticoagulant effects is required. On the other hand, lowmolecular- weight heparin (LMWH) and fibrinolytic agents need to be monitored only under certain circumstances.
Richard C. Becker, Frederick A. Spencer
openaire +1 more source
Because of the narrow therapeutic index of warfarin and unfractionated heparin (UFH), monitoring their anticoagulant effects is required. On the other hand, lowmolecular- weight heparin (LMWH) and fibrinolytic agents need to be monitored only under certain circumstances.
Richard C. Becker, Frederick A. Spencer
openaire +1 more source
Anticoagulation clinics and the monitoring of anticoagulant therapy
International Journal of Cardiology, 1988Patients attending an anticoagulation clinic were studied to delineate predisposing risk factors for bleeding and thromboembolic episodes. Seventy-three patients were observed for a total of 921.8 patient-treatment months. The mean duration of treatment was 12.6 months (range 3-36 months).
Richard Charney +3 more
openaire +3 more sources